Stem cell research hits the French political agenda
This article was originally published in Clinica
Executive Summary
Embyronic stem cell research has risen to the top of the French political agenda, one month after both Houses of the UK Parliament voted in favour of using this ethically sensitive technique (see Clinica No 943, p 5). But with a presidential election next year, the French politicians are treating the delicate subject with extreme caution. As the President, Jacques Chirac, and the Prime Minister, Lionel Jospin, represent opposing views, the parliamentary debate could be long and slow.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.